Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for diabetes and obesity [3] Group 1: Company Presentation - Mick Hitchcock, Ph.D., Interim CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1] - The conference will take place from January 12-15, 2026, with one-on-one meetings hosted by Biomea's management team [1] Group 2: Company Mission and Products - Biomea is advancing therapies icovamenib and BMF-650, targeting metabolic disorders affecting nearly half of Americans and one-fifth of the global population [3] - The company's mission is to deliver transformative treatments aimed at curing diabetes, obesity, and related conditions [3]